文献速递免疫规划传染病防控与疫情报告

基于PCV2b的实验性疫苗在PCV2b与猪肺炎支原体共感染猪模型中的有效性

A Porcine circovirus type 2b (PCV2b)-based experimental vaccine is effective in the PCV2b-Mycoplasma hyopneumoniae coinfection pig model.
PubMed 文献 · Vaccine · 2019-09-16

本研究评估基于PCV2b的实验性亚单位疫苗在PCV2b与猪肺炎支原体共感染猪模型中的效力。49头3周龄无PCV2和猪肺炎支原体感染的猪随机分为四组,疫苗接种组在3周龄免疫,双剂组在5周龄加强,所有猪(除阴性对照组)在初免后28天感染猪肺炎支原体,一周后挑战PCV2b,挑战后21天剖检。结果显示疫苗接种显著降低PCV2b病毒血症并减少或消除PCV2相关淋巴组织病变,两剂方案较一剂方案有一定优势,两种方案均在挑战前诱导针对PCV2a和PCV2d的中和抗体。

要点

  • PCV2b实验性疫苗在共感染模型中降低病毒血症和淋巴病变。
  • 两剂方案较一剂方案有一定优势。
  • 两种方案均诱导针对PCV2a和PCV2d的中和抗体。

核心结论

  • 在该研究条件下,实验性PCV2b疫苗保护常规生长猪抵抗PCV2b病毒血症及相关病变,两剂方案较一剂方案有一定优势。

研究设计与样本

  • 研究使用49头3周龄无PCV2和猪肺炎支原体的猪,随机分为阴性对照组、阳性对照组、单剂疫苗组和双剂疫苗组。
  • 单剂组和双剂组在3周龄接种,双剂组在5周龄加强;除阴性对照组外,所有猪在初免后28天感染猪肺炎支原体,一周后挑战PCV2b,挑战后21天剖检。

主要发现

  • 在PCV2b挑战前,两个疫苗组均产生可检测的针对PCV2的体液和细胞免疫应答。
  • 与阳性对照组相比,疫苗接种显著降低PCV2b病毒血症,并减少或消除PCV2相关淋巴组织病变。
  • 两种免疫方案均在挑战前诱导针对PCV2a和PCV2d的中和抗体。

临床怎么用

  • 在PCV2b与猪肺炎支原体共感染风险较高的猪群中,基于PCV2b的疫苗可考虑用于减少病毒血症和相关病变。
  • 两剂免疫方案可能较一剂方案提供一定优势,但需结合现场情况评估。

局限性

  • 研究为实验性共感染模型,样本量有限(49头猪),结果外推至田间需谨慎。
  • 研究未报告田间实际生产性能指标和长期保护效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Porcine circovirus type 2 (PCV2) is one of the major swine pathogens causing high economic losses due to PCV2-associated disease (PCVAD). PCV2 infection is not only immunosuppressive by damaging lymphoid tissues but is also exacerbated by co-infections with other pathogens including Mycoplasma hyopneumoniae. While PCV2 can be divided into several genotypes, currently only PCV2a, PCV2b and PCV2d are globally prevalent and considered of major importance. Most commercial PCV2 vaccines are based on PCV2a isolates; however, the high prevalence of PCV2b and PCV2d in the global pig population is raising concerns among pig veterinarians. The objective of this study was to evaluate the efficacy of an experimental PCV2b-based subunit vaccine in a combined PCV2b and M. hyopneumoniae coinfection model. Briefly, a total of 49 PCV2- and M. hyopneumoniae-free 3-week-old pigs were randomly divided into four groups: A non-vaccinated, non-infected NEG-CONTROL group, a non-vaccinated, PCV2b-infected, POS-CONTROL group, and two vaccinated and PCV2b-infected groups (SINGLE-VAC, DUAL-VAC). SINGLE-VAC and DUAL-VAC pigs were vaccinated at 3 weeks of age and DUAL-VAC pigs received a booster dose at 5 weeks of age. All pigs, except NEG-CONTROLs, were experimentally infected with M. hyopneumoniae 28 days after initial vaccination and challenged with PCV2b one week later. The pigs were necropsied 21 days after PCV2b challenge. Prior to PCV2b challenge, both vaccinated groups had detectable humoral and cell-medicated immune responses to PCV2. Vaccination significantly reduced PCV2b viremia and also reduced or eliminated PCV2-associated lymphoid lesions compared to the POS-CONTROL pigs. Under the study conditions, an experimental PCV2b vaccine protected conventional growing pigs against PCV2b viremia and associated lesions in a coinfection model with some advantages of the two-dose regimen versus the one dose regimen. Both protocols induced neutralizing antibodies against PCV2a and PCV2d prior to challenge.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Opriessnig T, Castro AMMG, Karuppanan AK, et al. A Porcine circovirus type 2b (PCV2b)-based experimental vaccine is effective in the PCV2b-Mycoplasma hyopneumoniae coinfection pig model. Vaccine. 2019. PMID: 31537445. doi:10.1016/j.vaccine.2019.09.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。